Figure 7.

(a) Schematic illustrations for the loading of Fe₃O₄/HAp NCs on A431 cell lines todetermine the cytotoxicity of the samples; (b) In vitro biocompatibility and cell proliferation of the Fe₃O₄/HAp NCs by MTT assay with different dosages of 10 to 500 μg mL⁻¹; (c) schematic diagram for andrographolide (20 μM) anti-cancer drug loading on Fe₃O₄/HAp NCs (50 μg mL⁻¹) treated with the A431 cell lines and (d) In vitro biocompatibility and cell proliferation of the andrographolide-Fe₃O₄/HAp NCs by MTT assay.